- Details
- (Length of Conversation: 24 min) Alicia Morgans and Charles Ryan discuss data that was presented at the ASCO GU 2018 meeting including two phase III trials, Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer ( SPARTAN ) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer ( PROSPER ) and the advances fo...
|
- Details
- Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Read Mor...
|
- Details
- Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. Biographies: Badrinath Konety, MD, MBA , is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncology and is Director of the...
|
- Details
- Karim Fizazi and Alicia Morgans discuss various treatment data in the metastatic hormone-sensitive space, including the LATITUDE, CHAARTED and STAMPEDE trials. The European Consortium Prostate Cancer Consortium in Europe (PEACE) trials were designed for the current generation of prostate and advanced prostate cancer patients and was established in 2013 to facilitate large academic clinical trials...
|
- Details
- (Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...
|
- Details
- (Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...
|
- Details
- Benjamin Brucker and Diane Newman discuss the nocturia patients she identifies and treats in her practice, the bothers they experience from nighttime awakenings, and sleep disruption outcomes in her patients' daily life. They also discuss conservative treatment approaches and antimuscarinic medications for overactive bladder. Biographies: Diane K. Newman, DNP, FAAN, BCB-PMD Benjamin M. Brucker, MD...
|
- Details
- Colleagues at the University of Pennsylvania, Ariana Smith, MD and Diane Newman, DNP discuss The Prevention of Lower Urinary Tract Symptoms, (PLUS), a consortium funded by the NIH and NIDDK. PLUS is a group of multidisciplinary researchers and practitioners that come from a broad range of expertise and the aim of the program is to plan, perform, and analyze the research studies that are needed to...
|
- Details
- (Length of Discussion: 20 min) There has been a limited number of new therapeutics, particularly in the area of patients who would benefit from advanced systemic bladder cancer treatments. Dr. Neal Shore reviews some pioneering work from the past such as MVAC and gemcitabine platinum based combinations but he notes those treatments are where things were left for many many years. The development of...
|
- Details
- Dr. Benjamin M. Brucker welcomes viewers to the new Nocturia Center of Excellence: the leading location for state of the art lectures, original articles, research, current treatments and emerging clinical care in pelvic health and pelvic floor dysfunction. Dr. Brucker encourages viewers to utilize this center as a resource for current research, clinical expertise and to stay up to date with curren...
|
